Vincristine Sulfate Liposome

DRUG10 trials

Sponsors

Children's Oncology Group, National Cancer Institute (NCI), Nanjing Luye Sike Pharmaceutical Co., Ltd., Wake Forest University Health Sciences, Northwestern University

Conditions

Adult Acute Lymphoblastic LeukemiaAdult RhabdomyosarcomaAllogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White CellsCD22 PositiveChildhood Alveolar RhabdomyosarcomaChildhood Embryonal Rhabdomyosarcoma

Phase 1

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

WithdrawnNCT02861040

Northwestern UniversityRecurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia

Start: 2016-08-31Updated: 2016-12-15

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

WithdrawnNCT03851081

Roswell Park Cancer InstituteAllogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells +5

Start: 2021-01-21End: 2024-01-21Updated: 2022-01-28

PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Acrotech Biopharma Inc.Hematologic Diseases

Start: 2020-08-15End: 2020-10-15Target: 56Updated: 2020-04-16

Phase 2

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

CompletedNCT01055314

National Cancer Institute (NCI)Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma +3

Start: 2010-01-31End: 2016-06-30Updated: 2017-08-29

Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

TerminatedNCT02337478

Wake Forest University Health SciencesRecurrent Adult Acute Myeloid Leukemia

Start: 2015-06-05End: 2017-09-04Updated: 2019-08-14

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

RecruitingNCT03136146

M.D. Anderson Cancer CenterRecurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia +8

Start: 2017-08-09End: 2027-08-01Target: 42Updated: 2026-02-17

Phase 3

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

CompletedNCT00025259

Children's Oncology GroupChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma +5

Start: 2002-09-30Updated: 2017-04-12

Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

Active, not recruitingNCT00379340

Children's Oncology GroupStage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor

Start: 2007-04-30End: 2026-11-18Updated: 2026-03-17

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

CompletedNCT00567567

Children's Oncology GroupLocalized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma +3

Start: 2007-11-05End: 2022-03-31Updated: 2022-04-28

Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Nanjing Luye Sike Pharmaceutical Co., Ltd.Adult Acute Lymphoblastic Leukemia

Start: 2013-06-30End: 2017-02-28Target: 480Updated: 2014-03-03

Related Papers

The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial

Nature Communications2025-02-1415 citations

Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5

Cancer2023-11-0715 citations

Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event-Free Survival in Intermediate and High-Risk Hodgkin Lymphoma

Blood2023-11-021 citations

Performance of Positron Emission Tomography at Diagnosis and Response Assessment in Low and Intermediate-Risk Nodular Lymphocyte Predominant Hodgkin Lymphoma

Blood2023-11-02

Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331

Blood2022-11-152 citations

Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children’s Oncology Group.

Journal of Clinical Oncology2022-06-01

Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.

2022-01-0120 citations

A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

Blood2021-10-2014 citations

Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group

Blood2020-12-1926 citations

Primary mediastinal large B‐cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy

British Journal of Haematology2020-05-296 citations

Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma

JAMA2019-08-27334 citations

Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma

Blood Advances2017-04-2432 citations

A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.

Journal of Clinical Oncology2016-06-2064 citations

Pharmacogenetics of treatment response in patients with high-risk neuroblastoma: A Children’s Oncology Group study.

Journal of Clinical Oncology2016-05-20

Omission of lung radiation in patients with stage IV favorable histology Wilms Tumor (FHWT) showing complete lung nodule response after chemotherapy: A report from Children’s Oncology Group study AREN0533.

Journal of Clinical Oncology2015-05-2020 citations

Augmentation of therapy for favorable-histology Wilms Tumor with combined loss of heterozygosity of chromosomes 1p and 16q: A report from the Children’s Oncology Group studies AREN0532 and AREN0533.

Journal of Clinical Oncology2015-05-2014 citations

Early results from Children’s Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).

Journal of Clinical Oncology2015-05-2010 citations

Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Children’s Oncology Group study AREN0533.

Journal of Clinical Oncology2014-05-2020 citations